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Abstract
Purpose. Methicillin-resistant Staphylococcus aureus (MRSA) colonizes the skin of hospitalized patients and is associated with
high morbidity and mortality. To prevent colonization and infection by S. aureus, better disinfection practices are required.
Therefore, we evaluated the effect of chlorhexidine whole-body washing on hospital-acquired S. aureus infections among
intensive care unit (ICU) patients in a tertiary hospital in Mexico.
Methodology. The study was conducted over 18 months to evaluate the effect of 2% chlorhexidine gluconate (CXG) whole-
body washing of ICU adult patients on chlorhexidine and antibiotic resistance, biofilm production and clonal distribution of
S. aureus in a tertiary care hospital. Minimum inhibitory concentrations for CXG, antibiotic susceptibility and biofilm
production by S. aureus isolates were determined. Pulsed-field gel electrophoresis, multilocus sequence typing (MLST) and
PCR for Panton–Valentine leucocidin (PVL) were used for molecular typing of MRSA isolates.
Results/Key findings. We included 158 isolates. A reduction in antibiotic resistance in the study period was observed for
clindamycin, levofloxacin, norfloxacin, oxacillin and trimethoprim/sulfamethoxazole. None of the isolates showed reduced
susceptibility to CXG. Most of the isolates were non-biofilm producers (147/158). The most commonly identified clone was a
descendant of the ST5-MRSA-II (New York/Japan) clone. This clone decreased during the intervention period and reappeared
markedly in the post-intervention period. During the post-intervention period, two isolates were related with the clone
ST8-MRSA-IV (also known as USA300).
Conclusion. Our findings suggest that the CXG bathing favored the reduction of healthcare-associated MRSA isolates and a
temporary reduction of the predominant ST5-MRSA-II (New York/Japan) clone.
INTRODUCTION
Hospital-acquired skin infections due to a variety of bac-
terial species are common. Infection with methicillin-
resistant Staphylococcus aureus (MRSA) is of particular
interest because it is associated with substantial morbidity
and mortality. Among the virulence factors for increased
MRSA morbidity and mortality rates are biofilm produc-
tion (occurrence rate, 68.3 %) [1] and the emergence,
more than a decade ago, of community-acquired MRSA
(CA-MRSA) strains in healthy persons without predispos-
ing risk factors [2–5].
A limited number of MRSA lineages have emerged from the
transfer of the staphylococcal cassette chromosome mec into
successful methicillin-susceptible S. aureus (MSSA) clones.
Using multilocus sequence typing (MLST), Enright et al. dem-
onstrated that MRSA clones evolved from five different
groups of related genotypes or clonal complexes, each arising
from a distinct ancestral genotype [6–8]. The ST5-MRSA-II
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(or New York/Japan) clone has been shown to be particularly
successful in establishing itself in Mexico [9, 10].
Chlorhexidine gluconate (CXG) has a broad activity against
Gram-positive and Gram-negative bacteria [11]. Daily CXG
bathing of intensive care unit (ICU) patients has been
shown to reduce the risk of the acquisition of multidrug-
resistant organisms and the development of hospital-
acquired bloodstream infections [12]. A particular impact
has been seen on infection and colonization by MRSA.
Daily CXG whole-body baths are associated with a
decreased rate of colonization by MRSA and a lower rate of
MRSA ventilator-associated pneumonia [13, 14].
Although it is known that CXG baths reduce MRSA acquisi-
tion [15], so far there is no evidence concerning the molecu-
lar behavior of S. aureus during the CXG baths.
The aim of this study was to evaluate the effect of 2%
CXG whole-body washing on chlorhexidine and antibiotic
resistance, biofilm production and the clonal distribution
of S. aureus among adult ICU patients in a tertiary care
hospital.
METHODS
Ethics statement
This research was performed according to the principles
expressed in the Declaration of Helsinki with approval from
the Ethics Committee of the Universidad Autónoma de
Nuevo León (approval NM12-009). Informed consent was
obtained from all patients.
Study design
The study was conducted at the Hospital Universitario Dr
Jose Eleuterio Gonzalez, a 460-bed tertiary care hospital in
Monterrey, Mexico. This study was performed in the adult
medical and surgical ICUs (a 20-bed combined unit).
During the 1.5-year study period, we included a pre-
intervention period (1 January to 30 June 2012), an inter-
vention period (1 July to 31 December 2012) and a post-
intervention period (1 January to 30 June 2013). We
included one isolate per patient.
Selection of patients and whole-body washing
Exclusion criteria were a history of allergy to CXG, burns
on more than 20% of the total skin surface, and pregnancy.
Only patients older than 18 years were included. Patients
were subject to daily whole-body washing with 2% CXG-
impregnated wipes (Clorhexi-Wipes, G70 antisepsis, León,
Guanajuato, Mexico). In the intervention period, enrolled
patients received daily CXG baths during the complete
ICU stay.
Staphylococcus aureus isolates
S. aureus from any specimen classified as a potential causative
agent of infection according to standard procedures
was included [16]. Microbiological identification was per-
formed using Sensititre panels (TEK Diagnostic Systems, Inc.,
Cleveland, OH), according to the manufacturer’s instructions.
A coagulase tube test was carried out on all isolates.
Chlorhexidine and antibiotic susceptibility testing
Minimal inhibitory concentrations (MICs) for CXG were
determined using the agar dilution method, as recom-
mended by the Clinical Laboratory Standard Institute
(CLSI) in documents M07-A10 and M100-S26 [17]. For
CXG, the isolates with MIC values higher than the MIC90
value were classified as isolates with disinfectant-reduced
susceptibility [18]. The antibiotic susceptibility of all iso-
lates collected was determined using the broth microdilu-
tion method, as recommended by the CLSI [17], using
Sensititre panels following the manufacturer’s instruc-
tions. Antimicrobial testing included the determination of
resistance to cefoxitin, clindamycin, erythromycin, levo-
floxacin, linezolid, nitrofurantoin, norfloxacin, oxacillin,
penicillin, quinupristin/dalfopristin, teicoplanin, tetracy-
cline, trimethoprim/sulfamethoxazole and vancomycin.
Isolates were classified as MRSA when the MIC values for
oxacillin and cefoxitin were 4 and 8, respectively [17].
Production of biofilm
Semi-quantitative determination of biofilm production was
performed using crystal violet staining [19]. Isolates were
tested in quadruplicate in two independent experiments car-
ried out on different days. Isolates were cultured in trypti-
case soy broth supplemented with 1% glucose in 96-well
flat-bottom untreated polystyrene plates with low-
evaporation lids. After staining with 0.1% crystal violet, the
biofilm was dissolved in 95% ethanol, and the optical den-
sity at 595 nm (OD595) was measured. Isolates with an
OD595 0.12 were considered non-biofilm producers, weak
biofilm producers were identified by 0.13<OD595 <0.24, and
an OD595 0.25 was interpreted as indicating strong biofilm
producers. S. aureus ATCC 29213 (positive biofilm) and
S. hominis ATCC 27844 (negative biofilm) were used as
control strains.
Molecular typing
Pulsed-field gel electrophoresis (PFGE) was used for the
molecular typing of MRSA isolates. Genomic DNA was
prepared as described previously [20]. After digestion with
SmaI endonuclease (New England BioLabs, Hitchin, UK),
the DNA was separated in a CHEF-DRII apparatus (Bio-
Rad, Birmingham, UK). Strains NCTC8325 and BK2464
(kindly provided by Professor Herminia de Lencastre from
the Molecular Genetics Laboratory Institute de Tecnología
Química e Biologica da Universidad Nova de Lisboa) and
the USA300 strain were included as controls. The criteria
of Tenover et al. were used to compare different clones
[21]. PFGE gel images were analysed by visual inspection.
Isolates showing identical or related PFGE patterns were
considered to belong to the same clone. Clones were
labelled with a capital letter (A, B, C, etc.) and related pro-
files were indicated by adding a number (A1, A2, B1, B2,
etc.). The PFGE profiles of these strains were compared to
control strains.
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For isolates with PFGE patterns similar to MRSA USA300,
the presence of Panton–Valentine leucocidin (PVL) was
detected by PCR [22], with USA300 as a control. MLST was
performed as previously described [23]. The assignment of
alleles and sequence types (ST) was performed using soft-
ware from the Multi Locus Sequence Typing website, avail-
able at www.mlst.net.
Statistical analyses
Data were analysed using the statistical program SPSS ver-
sion 20.0 (SPSS, Inc., Chicago, IL, USA). The correlation
between the MIC values for CXG and antimicrobial agents
and the production of biofilm were determined using Spear-
man’s rank correlation test. One-way ANOVA with post hoc
Holm–Sidak tests was performed to compare the MIC of
CXG, PFGE types and biofilm production. P0.05 was con-
sidered to be statistically significant.
RESULTS
Patients and isolates collected
The study enrolled 327 participants, of whom 158 had an
S. aureus-positive culture. The mean age was 43.7 years ±SD
17.9, with a range of 17–85, and 111 were male and 47 were
female. A clinical summary of 156 patients is shown in
Table 1 [we were unable to obtain clinical data from two
patients (females)]. The mean length of stay for the patients
was 23.5 days, and most patients with S. aureus-positive cul-
tures had received cephalosporins (41.67%). Specimens
were isolated from 149 respiratory samples [tracheal aspi-
rate (n=121), bronchial lavage (n=26) and sputum (n=2)], 4
blood samples, 3 wounds, 1 cerebrospinal fluid sample and
1 urine sample. The isolate distribution was: 61 isolates (41
MRSA and 20 MSSA) in the pre-intervention period, 52 iso-
lates (29 MRSA and 23 MSSA) during the intervention
period and 45 isolates (12 MRSA and 33 MSSA) in the post-
intervention period.
Minimal inhibitory concentrations of chlorhexidine
and antibiotics
The distribution of the MIC of CXG and antibiotics for the
S. aureus isolates is shown in Table 2. None of the isolates
showed reduced susceptibility to CXG. The MIC50 and
MIC90 did not change for clindamycin, erythromycin, line-
zolid, norfloxacin, penicillin, quinupristin/dalfopristin, tei-
coplanin, tetracycline, trimethoprim/sulfamethoxazole or
chlorhexidine throughout the study. A decrease in the
MIC50 value was detected for levofloxacin (from 2 in the
pre-intervention period to 1 as of the intervention period).
A reduction in antibiotic resistance was detected for clinda-
mycin (P=0.042), levofloxacin (P=0.013), norfloxacin
(P=0.022), oxacillin (P=0.003) and trimethoprim/sulfameth-
oxazole (P=0.592). There was no vancomycin and linezolid
resistance. No correlation was found the antibiotic resis-
tance and the MIC for CXG. Overall, a significant reduction
in the frequency of MRSA isolates as an effect of the CXG
bathing (P=0.003) was detected.
Biofilm production
Only 5/158 (3.16%) of the isolates were strong biofilm pro-
ducers, with four of these being collected during the inter-
vention period. Six isolates (3.8%) were weak biofilm
producers and 147/158 (93.0 %) isolates did not produce
biofilm (Fig. 1). No significant differences in biofilm
production were observed between isolates collected in the
pre-intervention period and those collected during the
intervention period (P=0.168).
Analysis of clonal relatedness
All strains of S. aureus (n=158) were analysed by PFGE; 82
strains were MRSA and 76 strains were MSSA. MSSA
strains were detected in all three periods, but were more fre-
quent in the post-intervention period (n=33) than in the
intervention (n=23) and pre-intervention (n=20) periods.
The opposite was observed for MRSA strains, which were
less abundant in the post-intervention period (n=12) than
in the intervention (n=29) and pre-intervention (n=41)
periods (Table 3). PFGE analysis separated the S. aureus
strains into 24 different patterns (A–W; Fig. 2). PFGE pat-
tern C and subtypes predominated in this study; these pat-
terns were related to the ST5-MRSA-II (New York/Japan)
clone. Profiles C and C34 were the most frequent; pattern C
was detected in only MRSA strains in all three periods.
Table 1. Clinical data of included patients
Characteristic Total (n=156*)
Male gender, n (%) 111 (71.2)
Reason for ICU admission
Neurosurgery, n (%) 53 (34)
Multiple trauma, n (%) 11 (7.1)
Medical, n (%) 62 (39.7)
Other surgery, n (%) 30 (19.2)
Comorbidities
Chronic renal insufficiency, n (%) 9 (5.8)
Neoplasia, n (%) 13 (8.3)
Hospitalization >72 h in the last 12 months n (%) 14 (9.0)
Length of stay in days, mean (±SD) 23.5 (4–72)
Length of stay before isolation in days, mean (±SD) 6 (2–26)
Length of stay after isolation in days, mean (±SD) 15 (1–56)
Days of central venous catheter, mean (±SD) 10.5 (2–39)
Days of bladder catheter, mean (±SD) 11(2–39)
Days of mechanical ventilation, mean (±SD) 10 (2–39)
Antibiotics received before isolation
Cephalosporin n (%) 65 (41.7)
Fluoroquinolones n (%) 14 (9.0)
Vancomycin n (%) 24 (14.5)
Carbapenems n (%) 27 (17.3)
Others n (%) 26 (16.7)
Days of antibiotic use before isolation, median (range) 5 (2–25)
Number of antibiotics before isolation, mean (range) 2 (1–4)
*We obtained clinical data from 156 patients.
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Profile C34 was present in both MRSA and MSSA. Further-
more, during the post-intervention period, two isolates
(PVL+ and ST8) were related to the ST8-MRSA-IV
(USA300) clone (Table 3).
The highest clonal diversity was identified during the inter-
vention period. The ST5-MRSA-II (New York/Japan) clone
decreased significantly in the intervention period, but recov-
ered in the post-intervention period.
Among the MSSA strains during the post-intervention
period, there was a predominance of subtypes of the ST5-
MRSA-II (New York/Japan) clone (20/33), where only 13
isolates (patterns D, E, F1, I, T, U, V and X) were not related
to this clone (Fig. 2). Patterns D, E, F1 and I were also pres-
ent in the preceding periods.
In the pre-intervention period (41 MRSA isolates), there
was a marked predominance (37/41; 90.4%) of the ST5-
MRSA-II-New York/Japan clone (pattern C and subtypes).
In the intervention period, 15/29 (51.8%) of the isolates
belonged to the ST5-MRSA-II New York/Japan clone, and
in the post-intervention period, most MRSA strains (10/12;
83.3%) belonged to the New York/Japan lineage. As can be
seen, the ST5-MRSA-II New York/Japan clone decreased
Table 2. Distribution of chlorhexidine and antibiotic MIC50 and MIC90 values (µgml
 1) for S. aureus isolates
Period Antibiotic*
CLI ERY LEV LZD NIT NOR OXA PEN SYN TEC TET SXT VAN CXG
Pre-intervention MIC50 2 4 2 4 32 8 4 2 1 8 2 2/38 2 8
MIC90 2 4 2 4 64 8 4 2 1 8 2 2/38 4 32
% R 68.7 68.7 56.7 0 1.5 58.2 65.7 91 3 4.5 3 7.5 0 NA
% S 31.3 31.3 43.3 100 98.5 41.8 34.3 9 97 95.5 97 92.5 100 NA
Intervention MIC50 2 4 1 4 32 8 4 2 1 8 2 2/38 2 8
MIC90 2 4 2 4 32 8 4 2 1 8 2 2/38 2 32
% R 74.1 72.2 52.3 0 0 55.5 55.5 83.4 1.5 1.5 3 4.5 0 NA
% S 25.9 27.8 47.7 100 100 44.5 44.5 16.6 98.5 98.5 97 95.5 100 NA
Post-intervention MIC50 2 4 1 4 32 8 1 2 1 8 2 2/38 2 8
MIC90 2 4 2 4 64 8 4 2 1 8 2 2/38 4 32
% R 34.8 67.4 34.8 0 1.5 34.8 32.6 86.9 1.5 4.5 3 3 0 NA
% S 65.2 32.6 65.2 100 98.5 65.2 67.4 13.1 98.5 95.5 97 97 100 NA
MIC50 and MIC90: minimal inhibitory concentration (µg ml
 1) that inhibits 50 and 90% of isolates, respectively; % R and % S: percentage of isolates
resistant and susceptible, respectively; this classification was according to the cut-offs proposed by the CLSI.
*CLI, clindamycin; ERY, erythromycin; LEV, levofloxacin; LZD, linezolid; NIT, nitrofurantoin; NOR, norfloxacin; OXA, oxacillin; PEN, penicillin; SYN, quinu-
pristin/dalfopristin; TEC, teicoplanin; TET, tetracycline; SXT, trimethoprim/sulfamethoxazole; VAN, vancomycin; CXG, chlorhexidine.
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Fig. 1. Biofilm production of isolates among the three study periods.
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during the intervention period and recovered markedly in
the post-intervention period (Fig. 3).
DISCUSSION
Healthcare-associated infections are a major problem in
hospitals. CXG whole-body washing has been proposed to
reduce colonization and infection by some pathogens, espe-
cially S. aureus. In this study, we evaluated the effect of 2%
CXG whole-body washing on the antibiotic resistance, bio-
film production and clonal distribution of S. aureus among
ICU patients in a tertiary care hospital. Antibiotic resistance
diminished significantly for clindamycin (from 69 to 35%),
levofloxacin (from 57 to 35%) and norfloxacin (from 58 to
35%). Interestingly, in the pre-intervention period, 65.7%
of the isolates were oxacillin-resistant and in the post-
intervention period this percentage reduced to 32.6%. This
result indicates a significant reduction in the frequency of
MRSA isolates as a result of the CXG bathing (P=0.003).
To highlight the importance of this effect, we compared
these data to the prevalence of MRSA in the ICU in 2011
(62%) [24] and 2014 (32.14%) (data not published). As can
be seen, the MRSA frequency was maintained after CXG
bathing. Importantly, although the CXG baths were stopped
after the intervention period, MRSA colonizations have
been low ever since.
Our report confirms previous research on the usefulness of
CXG bathing to reduce MRSA frequency [15, 25]. Remark-
ably, there was no increase in resistance for any of the anti-
biotics evaluated against S. aureus in this study.
In general, most of the isolates were non-biofilm producers.
Some reports show a moderate biofilm production by
S. aureus. For example, a study in India revealed that 55%
of isolates produced biofilm, with 76.6% of MRSA produc-
ing biofilm in comparison to 38.8% of MSSA [25]. Further-
more, an association between biofilm formation and the
special molecular characteristics of MRSA has been
reported. Among 126 isolates, 68.3% were biofilm pro-
ducers (5 strong producers and 81 weak producers) and
these were more likely to be multidrug-resistant than non-
biofilm-forming isolates [1]. In our study, there was no
correlation between biofilm production and antibiotic resis-
tance, and most of the isolates were non-biofilm producers.
We hypothesize that the low frequency of this virulence fac-
tor may have had a role in the reduction of the MRSA
percentages.
A few MRSA pandemic clones have spread worldwide,
and the ST5-MRSA-II New York/Japan clone has estab-
lished itself in Mexico [9]. In our study, we detected a
remarkable diversity of clones, but two clones predomi-
nated, both descendants of the ST5-MRSA-II New York/
Japan clone. Interestingly, the ST5-MRSA-II New York/
Japan clone decreased during the intervention period, but
this displacement was temporal because the clone reap-
peared strongly in the post-intervention period. This sin-
gularity may be relevant to the predominance of this
pandemic clone. To our knowledge, this phenomenon has
not previously been reported. The ST5-MRSA-II New
York/Japan clone has been reported in five hospitals in
this city apart from ours [10].
Table 3. Distribution of PFGE patterns for MRSA and MSSA isolates in the study periods
Clones Pre-intervention period Intervention period Post-intervention period
MRSA (n=41) MSSA (n=20) MRSA (n=29) MSSA (n=23) MRSA (n=12) MSSA (n=33)
A, A1, B, C43, C3, C27, C41, R1 1
C* 17 10 5
C4, C25, C50, D, F1, I, T, W 1
C6, C27, D1, D2, G2, L1, M1, N, Ñ 1
C14 2 2
C28, C42, C43, C45, C46, D, F, F1, G, G1, H, R 1
C34* 14 5 3 12
C34, C44, F1, I 2
C47 3
C48 3
C49, U, V 2
D, G 2
I 4
E 2 4
E, F 3
F2, G2, H, J, K, O, P, Q, S 1
CA-MRSA 2
*Pattern C and subtypes represent strains of MRSA descendants of ST5-MRSA-II (New York/Japan) clone.
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In this study, two isolates from the post-intervention period
were revealed to be CA-MRSA and related to the ST8-
MRSA-IV (USA300) clone. This finding suggests that
USA300 isolates were acquired under CXG pressure during
the hospital stay rather than while in contact with the com-
munity. The ST8-MRSA-IV (USA300) clone predominates
in the United States [26] and has been reported in our city
[27]. In our hospital, we provided active surveillance of
MRSA and, based on finding the CA-MRSA (USA300) in
our hospital, we will implement molecular surveillance of
CA-MRSA.
In our study, a duration of stay of 23.5 days was detected,
and this is considered to be a long stay in the hospital. We
were not surprised, because the length of hospital stay has
been reported as a risk factor associated with MRSA acquisi-
tion during hospitalization (odds ratio 1.04, 95% confidence
interval 1.03–1.06, P<0.001) [28].
A potential bias of our study is the fact that the number of
patients in each study period was different. This difference
may reflect a difference in the number of patients seen in
the hospital during the three periods.
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Fig. 2. Distribution of PFGE patterns for S. aureus isolates in the study periods.
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In conclusion, our results suggest that CXG bathing fav-
oured the reduction of MRSA isolates by the selection of
MSSA and temporarily reduced the frequency of the ST5-
MRSA-II (New York/Japan) clone.
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